Related Experiment Videos
Hyperlipidemia after organ transplantation
1Department of Medicine, SUNY Health Science Center, Brooklyn 11203.
Insights
Post-transplant hyperlipidemia is a common complication, potentially causing accelerated atherosclerosis and graft loss. Different immunosuppressants like cyclosporine can lead to distinct lipid profiles, requiring careful management.
Area of Science:
- Nephrology
- Cardiology
- Immunology
Background:
- Hyperlipidemia is a frequent and challenging issue after organ transplantation.
- It may underlie accelerated atherosclerosis in heart transplant recipients and renal transplant patients.
- Hyperlipidemia might also contribute to long-term renal graft loss.
Purpose of the Study:
- To explore the causes and implications of hyperlipidemia in organ transplant recipients.
- To differentiate lipid abnormalities associated with specific immunosuppressive agents.
- To discuss initial therapeutic strategies for post-transplant hyperlipidemia.
Main Methods:
- Review of existing literature on post-transplant hyperlipidemia.
- Analysis of lipid profiles in patients treated with azathioprine/prednisone versus cyclosporine.
- Discussion of the potential mechanisms of hyperlipidemia induced by immunosuppressants.
Main Results:
- Hypertriglyceridemia is common with azathioprine and prednisone, linked to calorie intake and glucose intolerance.
- Hypercholesterolemia is more frequent with cyclosporine, potentially due to LDL receptor interference.
- Cyclosporine may also impact bile acid synthesis and glucose tolerance, exacerbating hyperlipidemia.
Conclusions:
- Post-transplant hyperlipidemia has varied causes depending on immunosuppressive therapy.
- Dietary modifications (calorie-fat restriction, fiber) are initial management steps.
- Pharmacologic lipid-lowering agents require cautious use and further study in transplant patients.
Abstract:
Hyperlipidemia, long recognized as a difficult and common problem following organ transplantation, may be the underlying cause of the accelerated atherosclerosis observed in heart transplant recipients and children with renal transplants. In addition, hyperlipidemia may play a role in late renal graft loss. The cause of post-transplant hyperlipidemia is unclear. In patients treated with azathioprine and prednisone, hypertriglyceridemia is the commonest finding and probably results from an increased consumption of calories from carbohydrate and fat following resolution of uremia, in conjunction with glucose intolerance secondary to steroid administration. In patients treated with cyclosporine, hypercholesterolemia is the most common form of hyperlipidemia. Cyclosporine is a lipophilic drug that is transported in the plasma, largely in association with lipoproteins, and may require the low-density lipoprotein (LDL) receptor for internalization into cells. Hypercholesterolemia may result from interference with the basic cholesterol feedback mechanism via the LDL receptor. In addition, cyclosporine affects bile acid synthesis and worsens glucose tolerance, both factors that may promote hyperlipidemia. The first therapeutic approach to hyperlipidemia in the transplant recipient is dietary calorie-fat restriction and supplementation with soluble fiber. Ongoing clinical trials of the available pharmacologic lipid-lowering agents are addressing the safety and efficacy of these agents in the setting of immunosuppression; until that time, they should be used cautiously and in low doses.